Search
Nisin Z
go.drugbank.com/drugs/DB19122InvestigationalNisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).
Categories: Compounds used in a research, industrial, or household settingCEP-1347
go.drugbank.com/drugs/DB05403InvestigationalCEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons
Sulfamethazine
go.drugbank.com/drugs/DB01582ApprovedVet approvedWithdrawnIt has a spectrum of antimicrobial action similar to other sulfonamides.
Synonyms: N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide, N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamideNXN-188
go.drugbank.com/drugs/DB06096InvestigationalNXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Ametantrone
go.drugbank.com/drugs/DB21078ExperimentalAmetantrone is a small molecule drug. Ametantrone has a monoisotopic molecular weight of 412.21 Da.
Categories: Compounds used in a research, industrial, or household settingSmilagenin
go.drugbank.com/drugs/DB05450Investigationalin Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalIt has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels
CHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.